94 related articles for article (PubMed ID: 23734882)
1. Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure.
Mayer-Sonnenfeld T; Har-Noy M; Lillehei KO; Graner MW
Int J Hyperthermia; 2013 Sep; 29(6):520-7. PubMed ID: 23734882
[TBL] [Abstract][Full Text] [Related]
2. The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity.
Graner MW; Romanoski A; Katsanis E
Int J Hyperthermia; 2013 Aug; 29(5):380-9. PubMed ID: 23725202
[TBL] [Abstract][Full Text] [Related]
3. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
[TBL] [Abstract][Full Text] [Related]
4. Chaperone-rich cell lysates, immune activation and tumor vaccination.
Zeng Y; Graner MW; Katsanis E
Cancer Immunol Immunother; 2006 Mar; 55(3):329-38. PubMed ID: 15887013
[TBL] [Abstract][Full Text] [Related]
5. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.
Kislin KL; Marron MT; Li G; Graner MW; Katsanis E
FASEB J; 2007 Jul; 21(9):2173-84. PubMed ID: 17327358
[TBL] [Abstract][Full Text] [Related]
6. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers.
Graner MW; Zeng Y; Feng H; Katsanis E
Cancer Immunol Immunother; 2003 Apr; 52(4):226-34. PubMed ID: 12669247
[TBL] [Abstract][Full Text] [Related]
7. Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines.
Graner MW; Lillehei KO; Katsanis E
Front Oncol; 2014; 4():379. PubMed ID: 25610811
[TBL] [Abstract][Full Text] [Related]
8. Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine.
Epple LM; Bemis LT; Cavanaugh RP; Skope A; Mayer-Sonnenfeld T; Frank C; Olver CS; Lencioni AM; Dusto NL; Tal A; Har-Noy M; Lillehei KO; Katsanis E; Graner MW
Int J Hyperthermia; 2013 Aug; 29(5):390-8. PubMed ID: 23786302
[TBL] [Abstract][Full Text] [Related]
9. Intracellular and extracellular Hsp70 chaperone as a target for cancer therapy.
Guzhova IV; Shevtsov MA; Abkin SV; Pankratova KM; Margulis BA
Int J Hyperthermia; 2013 Aug; 29(5):399-408. PubMed ID: 23845032
[TBL] [Abstract][Full Text] [Related]
10. Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity.
Chen X; Zeng Y; Li G; Larmonier N; Graner MW; Katsanis E
Biol Blood Marrow Transplant; 2006 Mar; 12(3):275-83. PubMed ID: 16503496
[TBL] [Abstract][Full Text] [Related]
11. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values.
Luk JM; Lam CT; Siu AF; Lam BY; Ng IO; Hu MY; Che CM; Fan ST
Proteomics; 2006 Feb; 6(3):1049-57. PubMed ID: 16400691
[TBL] [Abstract][Full Text] [Related]
12. A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model.
Li G; Andreansky S; Helguera G; Sepassi M; Janikashvili N; Cantrell J; Lacasse CL; Larmonier N; Penichet ML; Katsanis E
Mol Cancer Ther; 2008 Mar; 7(3):721-9. PubMed ID: 18347157
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
14. Characterization of polyvalent allogeneic vaccines.
Van Epps D
Dev Biol (Basel); 2004; 116():79-90; discussion 133-43. PubMed ID: 15603185
[TBL] [Abstract][Full Text] [Related]
15. Cancer vaccination.
Del Vecchio M; Parmiani G
Forum (Genova); 1999; 9(3):239-56. PubMed ID: 10504171
[TBL] [Abstract][Full Text] [Related]
16. Proteins upregulated by mild and severe hypoxia in squamous cell carcinomas in vitro identified by proteomics.
Sørensen BS; Horsman MR; Vorum H; Honoré B; Overgaard J; Alsner J
Radiother Oncol; 2009 Sep; 92(3):443-9. PubMed ID: 19541378
[TBL] [Abstract][Full Text] [Related]
17. Proteomic profiling of human retinal and choroidal endothelial cells reveals molecular heterogeneity related to tissue of origin.
Zamora DO; Riviere M; Choi D; Pan Y; Planck SR; Rosenbaum JT; David LL; Smith JR
Mol Vis; 2007 Oct; 13():2058-65. PubMed ID: 18079679
[TBL] [Abstract][Full Text] [Related]
18. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic cancer vaccines: using unique antigens.
Lewis JJ
Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14653-6. PubMed ID: 15297620
[TBL] [Abstract][Full Text] [Related]
20. High throughput proteomic strategies for identifying tumour-associated antigens.
Gunawardana CG; Diamandis EP
Cancer Lett; 2007 Apr; 249(1):110-9. PubMed ID: 17306453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
